A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma
A study for patients with MGMT-Methylated Glioblastoma using study drug temozolomide
Sponsor: BMS
Enrolling: Male and Female Patients
IRB Number: AAAQ8210
U.S. Govt. ID: NCT02617589
Contact: Fabio Iwamoto: 212-342-2959 / fi2146@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the body's immune system to work against tumor cells.
This study is closed
Investigator
Fabio Iwamoto, MD
Do You Qualify?
Have you been diagnosed with glioblastoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Fabio Iwamoto
fi2146@cumc.columbia.edu
212-342-2959
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE